Ixabepilone in the treatment of breast cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Algorithms for the treatment of locally advanced metastatic breast cancer (mBC) provide for the consistent use of chemotherapy, and appointment of targeted therapy if necessary. Epothilone ixabepilone is a microtubule stabilizer approved as monotherapy and in combination with capecitabine for the treatment of mBC in patients with proven resistance to anthracyclines and taxanes. Chemotherapy and hormonal therapy form the basis of mBC treatment. The epothilone class of drugs is characterized by efficacy and safety in patients with disease progression during chemotherapy. In phase III studies, ixabepilone increased progression-free survival and overall response rates with a controlled toxicity profile. Recent subpopulation analyzes of large pooled datasets have shown improvements in progression-free survival and overall survival with ixabepilone in patients with triple-negative breast cancer and in patients who relapsed within 12 months of prior treatment. Additional study parameters for ixabepilone therapy discussed here include adjuvant therapy, weekly dosing regimens, and the use of ixabepilone in new treatment combinations. As with other microtubule stabilizers, treatment with ixabepilone may lead to peripheral neuropathy, but evidence-based treatment strategies may prevent these symptoms. Dose reduction did not appear to affect the efficacy of ixabepilone in combination with capecitabine. The inclusion of ixabepilone in individual treatment plans may increase progression-free survival in a population of patients with previous therapy failure.

Full Text

Restricted Access

About the authors

V. F Semiglazov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

P. V Krivorotko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

T. Yu Semiglazova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. V Komyakhov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

T. T Tabagua

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

Maria D. Kazantseva

N.N. Petrov National Medical Research Center of Oncology

Email: sokolmd_1998@mail.ru
St. Petersburg, Russia

E. K Zhiltsova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

D. G Ulrikh

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

M. V Chervyak

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. P Tergoeva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

V. V Klimenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

V. V Semiglazov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

References

  1. Семиглазова Т.Ю., Клюге В.А., Коробейникова Е.А. и др. Новые достижения в лечении рака молочной железы: роль эпотилонов. Медицинский совет. 2017;(6):72-83.
  2. Partridge A.H., Rumble R.B., Carey L.A., et al. Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or Unknown) Advanced Breast Cancer:American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. (2014) 32:3307-29. doi: 10.1200/JCO.2014.56.7479.
  3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer V2.2020. National Comprehensive Cancer Network (2020).
  4. Ibrahim N.K Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer. Front Oncol. 2021:11:61 7874.
  5. Krause W. Resistance to Anti-Tubulin Agents: From Vinca Alkaloids to Epothilones. Cancer Drug Resist (2019) 2:82-106. doi: 10.20517/cdr.2019.06
  6. Fojo T, Menefee M. Mechanisms of Multidrug Resistance: The Potential Role of Microtubule-Stabilizing Agents. Ann Oncol. 2007;18(Suppl. 5):v3-8. doi: 10.1093/annonc/mdm172.
  7. Christie E.L., Pattnaik S., Beach J., et al. Multiple ABCB1 Transcriptional Fusions in Drug Resistant High-Grade Serous Ovarian and Breast Cancer. Nat Commun. 2019;10:1295. doi: 10.1038/s41467-019-09312-9.
  8. Konieczkowski D.J., Johannessen C.M., Garraway L.A. A Convergence-Based Framework for Cancer Drug Resistance. Cancer Cell. 2018;33:801-15. doi: 10.1016/j.ccell.2018.03.025.
  9. Tsesmetzis N., Paulin C.B.J., Rudd S.G., Herold N. Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. Cancers (Basel). 2018;10(7):240. doi: 10.3390/cancers10070240.
  10. IXEMPRA (Ixabepilone) Injection [Prescribing Information. Princeton, NJ: R- Pharm US LLC (2016).
  11. Cobham M.V, Donovan D. Ixabepilone: A New Treatment Option for the Management of Taxane-Resistant Metastatic Breast Cancer. Cancer Manag Res. 2009;1:69-77. doi: 10.2147/CMAR.S5723.
  12. Vahdat L. Ixabepilone: A Novel Antineoplastic Agent With Low Susceptibility to Multiple Tumor Resistance Mechanisms. Oncologist. 2008;13:214-21. doi: 10.1634/theoncologist.2007-0167.
  13. Lee F.Y., Borzilleri R., Fairchild C.R., et al. BMS-247550: A Novel Epothilone Analog With a Mode of Action Similar to Paclitaxel But Possessing Superior Antitumor Efficacy. Clin Cancer Res. 2001;7:1429-37.
  14. Centers for Disease Control and Prevention. Healthcare Facilities, in: Managing Operations During the COVID-19 Pandemic (2020). Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-hcf.html (Accessed June 28, 2020).
  15. Perez E.A, Lerzo G., Pivot X., et al. Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. J Clin Oncol. 2007;25:3407-14. Doi: 10.1200/ JCO.2006.09.3849.
  16. Lechleider R.J., Kaminskas E., Jiang X., et al. Ixabepilone in Combination With Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies. Clin Cancer Res. 2008;14:4378-84. doi: 10.1158/1078- 0432.CCR-08-0015.
  17. Thomas E.S., Gomez H.L., Li R.K., et al. Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. J Clin Oncol. 2007;25:5210-17. doi: 10.1200/JCO.2007.12.6557.
  18. Hortobagyi G.N., Gomez H.L., Li R.K., et al. Analysis of Overall Survival From a Phase III Study of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With MBC Resistant to Anthracyclines and Taxanes. Breast Cancer Res Treat. 2010;122:409-18. doi: 10.1007/s10549-010-0901-4.
  19. Thomas E., Tabernero J., Fornier M., et al. Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer. J Clin Oncol. 2007;25:3399-406. Doi: 10.1200/ JCO.2006.08.9102.
  20. Li J., Ren J., Sun W. Systematic Review of Ixabepilone for Treating Metastatic Breast Cancer. Breast Cancer. 2017;24:171-79. doi: 10.1007/s12282-016-0717-0.
  21. Jassem J., Fein L., Karwal M., et al. Ixabepilone Plus Capecitabine in Advanced Breast Cancer Patients With Early Relapse After Adjuvant Anthracyclines and Taxanes: A Pooled Subset Analysis of Two Phase III Studies. Breast. 2012;21:89-94. doi: 10.1016/j.breast.2011.09.003.
  22. Roche H., Conte P., Perez E.A., et al. Ixabepilone Plus Capecitabine in Metastatic Breast Cancer Patients With Reduced Performance Status Previously Treated With Anthracyclines and Taxanes: A Pooled Analysis by Performance Status of Efficacy and Safety Data From 2 Phase III Studies. Breast Cancer Res Treat. 2011;125:755-65. Doi: 10.1007/ s10549-010-1251-y.
  23. Vahdat L.T., Vrdoljak E., Gomez H., et al. Efficacy and Safety of Ixabepilone Plus Capecitabine in Elderly Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. J Geriatr Oncol. 2013;4:346-52. doi: 10.1016/j.jgo.2013.07.006.
  24. Sparano J.A., Vrdoljak E., Rixe O., et al. Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. J. Clin. Oncol. 2010;28:3256-63. doi: 10.1200/JCO.2009.24.4244.
  25. Rugo H.S., Roche H., Thomas E., et al. Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple- Negative Breast Cancer: A Pooled Analysis From Two Large Phase III, Randomized Clinical Trials. Clin Breast Cancer. 2018;18:489-97. doi: 10.1016/j.clbc.2018.07.024.
  26. Campone M., Lacroix-Triki M., Roca L., et al. UCBG 2-08: 5-Year Efficacy Results From the UNICANCER-PACS08 Randomised Phase III Trial of Adjuvant Treatment With FEC100 and Then Either Docetaxel or Ixabepilone in Patients With Early-Stage, Poor Prognosis Breast Cancer. Eur J Cancer. 2018;103:184-94. doi: 10.1016/j.ejca.2018.06.025.
  27. Osborne C., Challagalla J.D., Eisenbeis C.F., et al. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-Neu Negative and Triple Negative Metastatic Breast Cancer. Clin Breast Cancer. 2018;18:e89-95. Doi: 10.1016/j. clbc.2017.07.002.
  28. Yardley D.A., Arrowsmith E.R., Daniel B.R., et al. TITAN: Phase III Study of Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Triple-Negative Breast Cancer. Breast Cancer Res Treat. 2017;164:649-58. doi: 10.1007/s10549-017-4285-6.
  29. Valero V. Managing Ixabepilone Adverse Events With Dose Reduction. Clin Breast Cancer. 2013;13:1-6. doi: 10.1016/j.clbc.2012.09.003.
  30. Valero V, Vrdoljak E., Xu B., et al. Maintenance of Clinical Efficacy After Dose Reduction of Ixabepilone Plus Capecitabine in Patients With Anthracycline-and Taxane-Resistant Metastatic Breast Cancer: A Retrospective Analysis of Pooled Data From 2 Phase III Randomized Clinical Trials. Clin Breast Cancer. 2012;12:240-46. Doi: 10.1016/j. clbc.2012.03.013.
  31. HALAVEN (Eribulin Mesylate) Injection [Prescribing Information. Woodcliff Lake, N.J., USA: Eisai, Inc.
  32. Vahdat L.T., Garcia A.A., Vogel C., et al. Eribulin Mesylate Versus Ixabepilone in Patients With Metastatic Breast Cancer: A Randomized Phase II Study Comparing the Incidence of Peripheral Neuropathy. Breast Cancer Res Treat. 2013;140:341-51. doi: 10.1007/s10549-013-2574-2.
  33. Vahdat L.T., Thomas E.S., Roche H.H., et al. Ixabepilone-Associated Peripheral Neuropathy: Data From Across the Phase II and III Clinical Trials. Support. Care Cancer. 2012;20:2661-68. Doi: 10.1007/ s00520-012-1384-0.
  34. Lee J.J., Swain S.M. Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents. J Clin Oncol. 2006;24:1633-42. Doi: 10.1200/ JCO.2005.04.0543.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies